Seattle Genetics Offers Updated Progression-Free Survival, Overall Survival Data from ADCETRIS Frontline PTCL Phase 1 Trial
September 24, 2014 at 09:01 AM EDT
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ADCETRIS (brentuximab vedotin) data to be presented at the 2014 European ...
